ClinicalTrials.gg
RecruitingNCT05067101Updated Oct 9, 2026

Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer

An interventional study of Capsule Sparing Cystectomy (CSC) and Conventional Radical Cystoprostatectomy (CRC) in Bladder Cancer, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Zhujiang Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
48th of 141
126 · median 75
Started
2024
with 23 others
No phase
33 of 194
20 open now
Primary completion
2028-12
later than 93 of 118 live
Registered
65th of 194
by date
Lead sponsor
6 of 194
Zhujiang Hospital

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 48th largest by planned enrollment of the 141 interventional ones that give a count, is one of 24 that started in 2024, is one of 33 with no phase, reaches primary completion later than 93 of the 118 other live ones, and was the 65th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient'survival and quality of life.

In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel without split it. This kind of neobladder is easier to construct and have less impact on intestinal function. So far, it has been implemented for more than 700 cases in Zhujiang hospital, the age of patients range from 9 months (bladder rhabdomyosarcoma) to 88 years old.

The filed of standard radical bladder cancer resection includes the structure of the prostate and seminal vesicles. More and more studies and long-term clinical experience in our hospital have confirmed that capsule sparing cystectomy can achieve good tumor control and excellent functional recovery.

Our project is going to perform a randomized controlled trial for capsule sparing cystectomy and conventional radical cystoprostatectomy and look forward to assess the oncology outcome and functional recovery of these two procedures which provide an objective basis for the patients undergoing orthotopic urinary diversion in the future.

Read the detailed description

CSC group:patients undergoing transurethral resection and enucleation of the prostate first, do not open the bladder neck to maintain the integrity of the bladder neck. The enucleated prostate capsule is preserved under laparoscopic surgery, and the urinary catheter is stretched during the operation to avoid implantation and metastasis.

CRC group:patients undergoing conventional radical cystoprostatectomy. All the patients undergoing detaenial sigmoid neobladder after cystectomy and accept at least 36 months follow up.

Followup: Patients were followed up at every 3-6 mo after surgery in the first 2 yr. The last follow-up was in the 36th month. Biochemical examination、blood and urine routine tests were done every 3 to 12 months. Urodynamic investigation, cystoscopic examination, pelvic computerized tomography, renal dynamic imaging and retro-cystogram were also performed every 3 to 12 months postoperatively.

Postoperative complications were classified as early (90 days or less) and late (greater than 90 days). Early and late complications were subdivided into those related and not related to the neobladder. Complication grade was classified according to the Clavien-Dindo system. Major complications were defined as grade III or higher.

During the follow-up period, patients were asked about daytime and night-time continence and erectile function (EF). Bladder Cancer Index and International Index of Erectile Function-5 (IIEF-5) are designed to evaluate patients' urinary control and sexual function

03

Conditions studied

  • Bladder Cancer

Keywords

  • bladder cancer
  • detaenial sigmoid neobladder
  • prostate capsule sparing
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males aged 20 and above and healthy volunteers are not accepted;
  • Bladder carcinoma in situ、T1G3 tumor、muscle invasive bladder cancer with clinical stage of cT2-T3N0M0 (If the clinical staging before therapy meets the inclusion criteria, patients who have decreased to below cT2 after neoadjuvant therapy can also choose to be included according to the patient's wishes).
  • Recurrent bladder cancer: recurrent NMIBC after treatment and Carcinoma in situ that does not respond to BCG vaccine treatment.
  • score is 0 or 1.
  • Voluntarily signed the .

Exclusion criteria

Exclusion Criteria:

  • Preoperative serum creatinine more than 2.26mg/dl Or 200μmol/L.
  • Cancer invaded prostate or urethral (confirmed by the pathology).
  • Patients with distant .
  • Abnormal PSA level, or suspected patients with unconfirmed prostate cancer .
  • A history of other malignant tumors within three years.
  • sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
  • Severe cardiopulmonary and liver dysfunction, combined with other serious diseases
  • Other conditions that have been approved by a urologist for not suitable for neobladder surgery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Capsule Sparing Cystectomy

    Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy

    Procedure: Capsule Sparing Cystectomy (CSC)

  • Placebo comparator
    Conventional Radical Cystoprostatectomy

    Patients undergoing conventional radical cystoprostatectomy

    Procedure: Conventional Radical Cystoprostatectomy (CRC)

Interventions

  • ProcedureCapsule Sparing Cystectomy (CSC)

    Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions

  • ProcedureConventional Radical Cystoprostatectomy (CRC)

    According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles

06

What researchers measure

Primary outcomes

  1. Post-operative urinary function

    Assess post-operative urinary function using the bladder cancer index (BCI) at the 12th month after surgery

    Time frame: At the 12th month after surgery

Secondary outcomes

  1. bladder cancer specific survival rate

    Determine bladder cancer control with CSC compared to CRC as measured by margin status and time to disease recurrence

    Time frame: 36 months

  2. Sexual function

    Assess post-operative sexual function using IIEF-5 score

    Time frame: 36 months

  3. Intraoperative conditions

    Including surgical time, bleeding volume, blood transfusion volume, etc.

    Time frame: 24 hour

  4. Early postoperative rehabilitation indicators

    Including intensive care time, time to restore full flow diet, hospitalization time, drainage tube removal time, visual pain score, etc

    Time frame: 30 days after surgery

  5. Rate of serious complications

    Assess rate of serious complications using Clavien Dindo Complication Grading System

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Chunxiao Liu
    Guangzhou, Guangdong 510282, China
    Recruiting
08

References and documents

Publications

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PubMed 35020204 ↗
  • Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, Hernandez V, Linares Espinos E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimae E, Ribal MJ, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29. PubMed 32360052 ↗
  • Xu K, Liu CX, Zheng SB, Li HL, Xu YW, Xu AB, Chen BS, Shen HY. Orthotopic detaenial sigmoid neobladder after radical cystectomy: technical considerations, complications and functional outcomes. J Urol. 2013 Sep;190(3):928-34. doi: 10.1016/j.juro.2013.03.072. Epub 2013 Mar 26. PubMed 23538237 ↗
  • Xu A, Li B, Li H, Zheng S, Du W, Xu Y, Zou Y, Luo Q, Liu C. Comparison of seromuscular tunnel and split-cuff nipple antireflux ureteroenteral anastomosis techniques in orthotopic taenia myectomy sigmoid neobladder: a prospective, randomized study. Urology. 2013 Mar;81(3):669-74. doi: 10.1016/j.urology.2012.11.018. Epub 2013 Jan 3. PubMed 23290142 ↗
  • Xu P, Chen C, Chen B, Bi E, Du W, Jiang N, Liu Z, Lan H, Cao M, Liu Y, Huang J, Shen H, Liu C, Liu C, Xu A. Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre. Eur Urol. 2022 Nov;82(5):543-550. doi: 10.1016/j.eururo.2022.08.015. Epub 2022 Aug 30. PubMed 36050131 ↗
  • Jacobs BL, Daignault S, Lee CT, Hafez KS, Montgomery JS, Montie JE, Humrich JE, Hollenbeck BK, Wood DP Jr, Weizer AZ. Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial. J Urol. 2015 Jan;193(1):64-70. doi: 10.1016/j.juro.2014.07.090. Epub 2014 Jul 24. PubMed 25066875 ↗
  • Hernandez V, Espinos EL, Dunn J, MacLennan S, Lam T, Yuan Y, Comperat E, Cowan NC, Gakis G, Lebret T, van der Heijden AG, Witjes JA, Ribal MJ. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urol Oncol. 2017 Sep;35(9):539.e17-539.e29. doi: 10.1016/j.urolonc.2017.04.013. Epub 2017 May 8. PubMed 28495555 ↗
  • Liu C, Zheng S, Li H, Xu K. Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics. J Urol. 2010 Dec;184(6):2440-5. doi: 10.1016/j.juro.2010.08.037. Epub 2010 Oct 16. PubMed 20952005 ↗
  • Chen P, Xu P, Liu C. Long-term outcomes of bipolar transurethral enucleation and resection of the prostate on patients with benign prostatic obstruction: a 10-year follow-up. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Dec;167(4):340-346. doi: 10.5507/bp.2022.034. Epub 2022 Jul 18. PubMed 35938386 ↗
  • Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007 May 1;109(9):1756-62. doi: 10.1002/cncr.22556. PubMed 17366596 ↗
  • Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol. 2010 May;183(5):1764-9. doi: 10.1016/j.juro.2010.01.013. Epub 2010 Mar 17. PubMed 20299056 ↗
  • Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2. PubMed 19638912 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2028, 50 months after the start.

Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 50 months is above that.

Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Dec 2028 and completion Dec 2026 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 5, 2021
StartActual
Sep 10, 2024
Primary completionEst.
Dec 1, 2028was Dec 2025
CompletionEst.
Jul 1, 2029was Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2025→Dec 1, 2028
Oct 9, 2026
Study completion
Dec 1, 2026→Jul 1, 2029
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Dec 1, 2025→Dec 1, 2028
    Study completion Dec 1, 2026→Jul 1, 2029
    + 5 other changes: identifiers, verification date, oversight details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05067101
Lead sponsor
Zhujiang Hospital
Responsible party
Chunxiao Liu (Professor;Chief Surgeon, Zhujiang Hospital) — Principal investigator
First posted
Oct 5, 2021
Start date
Sep 10, 2024
Primary completion
Dec 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Chunxiao Liu, doctor
Contact
liuchx888@163.com
+86 13302296795
Peng Xu, doctor
Contact
yihuixp88@hotmail.com
+86 18665073650
Chunxiao Liu, doctor
principal investigator · Southern Medical University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion